Epithalon vs Humanin
Comparison of Epithalon (Low evidence) and Humanin (Moderate evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Epithalon
Dossier overview
Humanin
Dossier overview
Overview
Epithalon and Humanin are both studied in the peptide research space.
Epithalon: A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan.
Humanin: A 24-amino acid mitochondria-derived peptide (MDP) discovered in 2001 that shows cytoprotective, anti-apoptotic, and neuroprotective effects in preclinical studies.
Evidence Comparison
| Aspect | Epithalon | Humanin |
|---|---|---|
| Evidence Level | Low | Moderate |
| Human Studies | 5 | 10 |
| Preclinical Studies | 15 | 40 |
| Total Sources | 28 | 50 |
Key Differences
| Aspect | Epithalon | Humanin |
|---|---|---|
| Category | Longevity | Longevity |
| Evidence Strength | Low | Moderate |
| Total Sources | 28 | 50 |
| Human Studies | 5 | 10 |
Summary
- Epithalon: Low evidence with 28 total sources (5 human)
- Humanin: Moderate evidence with 50 total sources (10 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.